Duplicate or split identity
Multiple records, conflicting identifiers or incorrect merges can break the patient-to-event relationship.
Healthcare & Life Sciences • Patient Data Quality
Patient Data Quality Consulting for Reliable Clinical, Operational and Research Decisions
DataConsultant helps healthcare and life-sciences organisations assess, govern and improve patient and clinical data across registration, care, interoperability, research, reporting and approved analytics or AI uses. We combine data profiling, patient-identity analysis, rule design, source-to-target traceability, interoperability checks, root-cause remediation and ongoing quality controls so teams can decide whether data is fit for its intended use.
Patient identity, demographics and duplicate-risk review
Clinical completeness, validity, timeliness and consistency controls
HL7/FHIR mapping, terminology and interface-quality checks where applicable
Traceable remediation, governance, release gates and monitoring
Scope depends on the intended use, data sources, interfaces, patient-identity model, jurisdictions, clinical or research context and required implementation support. Do not send patient-level data or protected health information through the initial enquiry form.
1
Purpose & Critical Data
- Patient journey/use case
- Critical data elements
- Source & interface scope
2
Profile & Trace
- Completeness & patterns
- Identity & duplicates
- Mapping & provenance
3
Multi-Dimension Review
- Validity & consistency
- Timeliness & terminology
- Interoperability checks
4
Failure Classification
- Patient-safety relevance
- Severity & detectability
- Root-cause hypothesis
5
Remediate & Re-test
- Source/mapping fixes
- Rule & workflow changes
- Evidence of closure
6
Release & Monitor
- Approve / condition
- Quarantine / rework
- Monitor residual risk
Evidence-Based Profiling
Patient-Identity Aware
Interoperability & Lineage
Privacy & Risk Aware
Operational Monitoring
02
Why Patient Data Quality Matters
Small defects can become large operational, research, reporting or safety risks when patient data crosses systems, interfaces, organisations and downstream decision workflows.
Missing clinical context
Absent allergy, medication, diagnosis, encounter or provenance context can make downstream data incomplete for its use.
Late or stale records
Delayed feeds, out-of-order events and timestamp inconsistencies can distort operational and longitudinal views.
Mapping & code mismatch
Interface transformations, units, code systems and local terminology can silently change meaning between source and target.
Analytics & AI distortion
Missingness, label defects, leakage, provenance gaps or non-representative data can weaken approved analytical or model use.
Interface truncation
Cardinality, required fields, parsing and transformation logic can create defects even when source data is correct.
Implausible values
Unexpected ranges, units, dates or combinations may require domain-aware review rather than generic validation alone.
Weak provenance
Teams cannot defend a decision when the source, transformation, rule version or correction history is unclear.
Privacy-context loss
Consent, purpose, access or de-identification context may not travel with patient-level data into downstream workflows.
No accountable owner
Quality alerts remain unresolved when clinical, operational, data and technology responsibilities are not explicit.
Patient-data defects should be prioritised by intended use and risk—not by a universal score. A record can be acceptable for one use and unsafe or misleading for another.
03
Current State → Target State
Move from reactive cleansing and local checks to a controlled patient-data quality capability with agreed use, ownership, evidence and release decisions.
Current State — Reactive & Fragmented
- Quality checks are embedded in individual reports or interfaces
- Patient matching exceptions have unclear ownership
- Clinical rules and thresholds are undocumented or inconsistent
- Source-to-target transformations are difficult to trace
- Quality issues are corrected downstream but recur upstream
- Interoperability defects surface only after exchange or release
- Analytics or AI teams inherit unexplained missingness and bias
- Monitoring focuses on counts rather than fitness for use
Target State — Governed & Traceable
- Critical patient data is defined by use case and risk
- Identity, demographic and longitudinal integrity are controlled
- Rules, thresholds and release actions have accountable owners
- Mappings, terminology and provenance are testable and versioned
- Root causes are assigned to source, interface or process owners
- Quality gates are integrated into delivery and interoperability flows
- Approved analytical and AI datasets carry quality evidence
- Monitoring shows residual risk, trends and exception closure
03A
Where Patient Data Quality Enters the Healthcare & Life-Sciences Value Chain
Patient information changes meaning and risk as it moves from identity and clinical interaction through diagnostics, exchange, research and downstream decision-making. Quality controls should follow that movement rather than sit only in the warehouse.
Registration & Identity
Identifiers, demographics, consent and patient matching.
Encounter & Care
Clinical documentation, diagnoses, problems and orders.
Diagnostics & Treatment
Labs, medications, observations, procedures and units.
Exchange & Transitions
Referrals, interfaces, mappings, terminology and provenance.
Operations & Quality
Scheduling, billing, quality programmes and service reporting.
Research & Trials
Registry, participant, study, EDC/ePRO and evidence workflows.
Outcomes, Analytics & AI
Approved reporting, analysis, prediction and model workflows.
Assess Where Patient Data Quality Risks Enter Your Workflow
Start with the use case, source systems, interfaces, patient-identity model and recurring defects. We can scope a focused assessment before a wider remediation programme.
05
What the Patient Data Quality Service Covers
The engagement is configured around the patient-data use, critical workflows, source and interface estate, evidence needs and risk profile. Not every capability is required in every assignment.
Direct Definition
What DataConsultant Does for Patient Data Quality
We connect the intended patient-data use to source evidence, critical-data definitions, reproducible rules, domain review, root-cause remediation, governance and monitoring. The goal is to make quality decisions traceable from the patient-data problem to the accountable fix and release decision.
- Assess fitness for a defined care, research, interoperability, reporting or analytical use
- Identify where defects originate across capture, mapping, integration and downstream processing
- Turn quality expectations into controlled rules, issue workflows and release criteria
When to Engage
Common Triggers for a Patient Data Quality Review
Typical triggers include an EHR or data-platform migration, new interoperability feed, recurring patient-identity issues, research or registry extraction, inconsistent quality reporting, a new longitudinal patient view, regulatory or audit findings, or preparation of patient data for approved analytics and AI.
- Before migration, interface or data-product release
- After recurring defects, reconciliation failures or trust issues
- When quality ownership and thresholds need to become operational
Data profiling & baseline
Measure patterns, missingness, distributions, duplicates, invalid values, freshness and cross-field consistency.
- Source-level profiling
- Trend and exception baseline
- Fitness-for-use findings
Patient identity quality
Assess identifiers, duplicate patterns, demographic conflicts, source keys and patient-to-event linkage.
- Duplicate-risk analysis
- Merge/unmerge context
- Longitudinal integrity
Critical-data rules
Translate clinical, operational, research and reporting expectations into testable controls and acceptance criteria.
- Rule catalogue
- Thresholds & severity
- Owner & response
Interoperability quality
Review source-to-target mappings, interface transformations, code systems and relevant HL7/FHIR expectations.
- Mapping checks
- Profile/conformance evidence
- Transformation defects
Terminology & standardisation
Assess local values, units, reference data and controlled terminology needed for consistent interpretation.
- Code-set alignment
- Unit consistency
- Reference-data controls
Failure & root-cause analysis
Separate symptoms from source, interface, workflow, mapping, ownership and control causes.
- Failure taxonomy
- Root-cause evidence
- Ownership assignment
Remediation & re-test
Prioritise fixes by risk, dependency and effort; verify corrections against agreed acceptance evidence.
- Remediation backlog
- Re-test pack
- Release criteria
Governance & monitoring
Define operational ownership, issue workflows, reporting, rule change control and continuous monitoring.
- Stewardship model
- Quality scorecards
- Continuous improvement
06
Patient Data Quality Dimensions
A single “quality score” is rarely sufficient. The review combines multiple dimensions and evaluates them against the defined patient, care, research, reporting or analytical purpose.
Patient Data
Fitness for Use
CompletenessValidity / ConformanceConsistencyTimelinessUniqueness / IdentityPlausibilityProvenanceIntegrityFitness for Use
Completeness
Required data is present for the intended process, patient journey and downstream use.
Validity & conformance
Values, structures, formats, cardinality and code expectations meet agreed rules.
Consistency
Related facts agree across fields, events, systems, interfaces and longitudinal records.
Timeliness
Data is available and updated within the window required by the use case.
Uniqueness & identity
Duplicate or split records do not undermine patient-to-event or participant linkage.
Plausibility
Values and combinations are credible for the domain and are escalated when domain judgement is needed.
Provenance & traceability
Source, transformation, rule version, correction and release evidence can be followed.
Integrity & relationships
Keys, references, encounter links and related entities remain intact through movement and transformation.
07
Evaluation Rules + Severity + Release Action
Rules should state what is checked, what evidence is needed, why failure matters, who decides severity and what happens before the data can be used.
| Quality area | Example evaluation question | Evidence | Example failure | Indicative severity | Potential release action |
|---|---|---|---|---|---|
| Patient identity | Can every event be linked to the correct patient or participant? | Identifiers, source keys, merge history, matching rules | Encounter linked to the wrong patient record | Critical | Block / investigate |
| Clinical completeness | Are required facts present for the defined use? | Critical-element rules, workflow context | Required allergy-status field absent from a care feed | High | Quarantine / rework |
| Validity | Are dates, units and values valid and plausible? | Reference lists, value constraints, domain review | Invalid unit or impossible event chronology | High | Rework / review |
| Interoperability | Does the payload meet the agreed interface/profile expectation? | Mapping specification, implementation guide, test cases | Required element dropped during transformation | High | Block interface release |
| Timeliness | Is the record available within the decision window? | Event/source timestamps, latency measures | Result arrives after the operational decision point | Medium/High | Condition / remediate |
| Provenance | Can source and transformations be traced? | Lineage, audit evidence, mapping versions | Derived value cannot be traced to source logic | Medium | Condition / evidence gap |
Illustrative examples only. Severity, tolerances and release actions must be calibrated to the specific process, patient-safety relevance, regulatory context, use case, detectability and agreed risk appetite.
08
Test Set + Evidence Design
A defensible assessment requires representative patient journeys, reproducible rules and traceable evidence—not isolated spot checks on convenient records.
Business / Clinical Use
Define the decision, process and intended use.
Representative Journeys
Cover relevant populations, pathways and exceptions.
Source & Interface Map
Identify systems, transformations and consumers.
Critical Data Set
Select fields, events and relationships that matter.
Acceptance Rules
Define logic, thresholds and severity.
Evaluate & Explain
Run checks, review exceptions and find causes.
Traceable Evidence
Retain reproducible findings and decisions.
09
Human + Automated Review Operating Model
Automation provides scale; healthcare and life-sciences judgement determines whether an exception is materially wrong, acceptable, clinically meaningful or dependent on context.
Turn Patient Data Rules Into a Repeatable Quality Gate
We can help define critical data, rule ownership, evidence, thresholds, exception workflows and release criteria that fit your specific care, interoperability, research or analytical use.
11
Failure Taxonomy + Remediation Ownership
Classifying defects consistently makes remediation more actionable and helps prevent downstream teams from repeatedly fixing symptoms.
Patient Data Failure Categories
Identity / matching failure
Missing / incomplete data
Invalid value or format
Cross-system inconsistency
Timeliness / sequencing issue
Terminology / unit mismatch
Mapping / transformation defect
Provenance / lineage gap
Consent / privacy-context gap
Interface / profile nonconformance
Unexpected duplication
Implausible combination / outlier
12
Patient Data Architecture + Evidence Flow
Quality must be controlled across the full path from patient interaction and source capture through interfaces, data platforms and approved downstream use.
1. Patient / Clinical Sources
- Registration, EHR/EMR and ADT
- Laboratory, pharmacy and radiology metadata
- Scheduling, portal and operational systems
- Research, registry, EDC/ePRO where applicable
2. Integration & Interoperability
- HL7/FHIR/API feeds where applicable
- File, batch and event integration
- Mappings, terminology and reference data
- Identity resolution and source keys
3. Governed Patient Data Layer
- Data models and trusted views
- Quality rules and exception workflow
- Metadata, lineage and provenance
- Access, masking and retention controls
4. Approved Consumption
- Care operations and quality improvement
- Research and trial analytics
- Reporting and interoperability services
- Approved BI, ML and generative-AI uses
Identity integrity
Quality gates
Provenance & lineage
Privacy / access
Monitoring & auditability
Patient & demographic data
Identifiers, demographics, contact, merge history, consent context and patient-to-encounter relationships.
Clinical event data
Encounters, diagnoses, problems, allergies, medications, observations, labs, procedures, orders and related metadata.
Research & trial data
Participant, protocol, visit, ePRO/eCOA, EDC or registry data when those workflows are in scope.
Metadata & control data
Mappings, code systems, lineage, rule definitions, audit evidence, issue history and release decisions.
13
Safety, Privacy, Policy + Governance Context
Patient-data quality cannot be separated from access, purpose, traceability and the controls governing how sensitive healthcare and research data is used.
Patient-safety escalation
Route defects with potential care or clinical impact to accountable clinical and safety owners.
Privacy & minimum data
Use only the patient-level data required for the approved task and control access accordingly.
Consent & purpose context
Preserve or assess the metadata needed to understand whether a downstream use is permitted.
Auditability & lineage
Maintain traceable source, transformation, rule version, correction and release evidence.
Accountable ownership
Assign decisions across clinical, operations, data, technology, research, privacy and risk functions.
AI dataset governance
Document approved use, provenance, quality evidence, access, evaluation boundaries and human review.
HL7 FHIRFHIR is an HL7 standard for healthcare data exchange. The applicable version and implementation guide must be confirmed.Official HL7 FHIR specification ↗
HIPAA Security Rule — USFor regulated entities, the rule addresses safeguards for electronic protected health information; applicability depends on role and context.HHS Security Rule summary ↗
DPDP Rules 2025 — IndiaIndia’s DPDP Rules and notified enforcement timeline may be relevant to personal-data processing depending on entity, purpose and commencement.MeitY DPDP Rules 2025 ↗
ICH E6(R3) GCPRelevant to clinical trials and research data when the engagement falls within applicable GCP responsibilities and regulated processes.ICH E6(R3) guideline ↗
FDA 21 CFR Part 11 contextElectronic-record and signature controls can matter where applicable predicate rules make records subject to Part 11.FDA Part 11 guidance ↗
Important: regulatory, privacy, clinical-safety and GxP requirements vary by jurisdiction, entity type, product, role, data use and system. DataConsultant can support evidence, governance and control design, but this service does not replace legal advice, regulatory interpretation, clinical-safety sign-off, formal validation or certification by appropriately qualified parties.
Secure the Patient Data Path Before Scaling Analytics, Research or AI
Use the quality review to expose identity, mapping, provenance, access and control gaps before downstream use expands.
13A
Patient Data Quality for Analytics + AI Readiness
Model or analytics readiness requires more than clean columns. Teams need to understand provenance, missingness, representativeness, label quality, approved use and monitoring boundaries.
Dataset fitness questions
Before patient or clinical data is used in approved BI, machine learning or generative-AI workflows, define the decision and evidence required.
RepresentativenessWhich populations, sites, pathways or time periods are missing?
Labels / ground truthWho defined the outcome and how reliable is the label?
ProvenanceCan the source, transformation and data version be reproduced?
Leakage riskDoes the dataset contain information unavailable at decision time?
Privacy & approved useIs access, purpose, minimisation and retention governed?
MonitoringHow will drift, missingness and source changes be detected?
AI data-control flow
Approved patient data
- Purpose & cohort documented
- Source and quality evidence
- Access and privacy controls
Training / grounding / evaluation
- Separated datasets where needed
- Missingness and label review
- Bias and leakage checks
Controlled model use
- Input/output monitoring
- Human review and escalation
- Evidence for changes
Patient Data Quality can strengthen the dataset evidence used by an AI-governance process. It does not guarantee model accuracy, clinical efficacy or safety.
14
Delivery Methodology
A structured engagement moves from purpose and evidence to root cause, remediation, re-test and controlled operational monitoring.
Scope & risk profile
Define the use case, patient journey, stakeholders and material risks.
Critical data & rules
Select patient data elements, relationships, definitions and thresholds.
Source & interface review
Map systems, transformations, terminology and evidence availability.
Profile & evaluate
Run reproducible checks and classify defects by dimension and use.
Validate exceptions
Review clinical/domain context and calibrate false positives.
Analyse root cause
Trace defects to source capture, interface, mapping, data model or process.
Remediate & re-test
Prioritise fixes, verify closure and document residual risk.
Release & monitor
Operationalise rules, owners, reporting, issue workflow and change control.
15
Decision Gates + Release Readiness
A release decision should be explicit: which criteria were met, which critical failures remain, who accepted residual risk and what monitoring follows.
Gate 1Purpose & criteria agreed
Gate 2Source and patient journeys covered
Gate 3Critical identity issues resolved
Gate 4Mappings & provenance traceable
Gate 5High-risk defects re-tested
Gate 6Residual risk reviewed
Gate 7Monitoring owner assigned
16
Tangible Patient Data Quality Deliverables
Outputs are designed to support decisions, remediation and governance rather than leave the organisation with an isolated profiling report.
Critical Data Inventory
Priority patient elements, definitions, uses and owners.
Profiling Baseline
Evidence by source, rule, dimension and patient journey.
Identity Findings
Duplicate, split-record and linkage-risk analysis.
Rule Catalogue
Testable logic, thresholds, owners and release actions.
Interoperability Findings
Mapping, terminology and conformance evidence where in scope.
Failure Taxonomy
Consistent issue types, severity and root-cause categories.
Remediation Backlog
Prioritised source, interface, platform and process fixes.
Root-Cause Findings
Traceable evidence connecting defects to accountable owners.
Severity / Risk Matrix
Decision rules for block, quarantine, condition or monitor.
Re-test Summary
Evidence of corrected failures and remaining exceptions.
Release-Readiness Pack
Criteria, decisions, residual risks and approvals.
Governance Pack
Owners, escalation, forums, rule change and issue workflow.
Monitoring Framework
Metrics, thresholds, review cadence and drift/change controls.
Implementation Plan
Sequenced changes, dependencies, acceptance criteria and handover.
16A
Implementation Support + Ongoing Patient Data Quality Operations
The engagement can continue beyond assessment so rules, remediations and governance become part of the actual patient-data lifecycle rather than a one-time report.
Implementation & remediation
Support rule engineering, mapping correction, data-pipeline controls, standardisation, quality dashboards, exception workflows and remediation delivery with internal teams or existing vendors.
- Prioritised mobilisation backlog
- Acceptance and re-test criteria
- Release coordination and handover
Target operating model
Clarify who owns patient-data definitions, rule approval, exception review, clinical escalation, source correction, privacy decisions, monitoring and quality change control.
- Data owner and steward responsibilities
- Clinical/domain review checkpoints
- Technology, privacy and risk escalation
Managed quality operations
Provide an agreed recurring service for profiling, rule monitoring, issue triage, threshold review, root-cause analysis, reporting, change control and continuous improvement.
- Scheduled quality monitoring
- Exception and SLA review
- Trend, drift and recurrence analysis
Move From Data Defects to a Defensible Patient Data Release Decision
Use a structured quality gate to connect evidence, root cause, remediation, residual risk and accountable approval before important patient data is reused or released.
18
Business Outcomes + Commercial Clarity
The objective is a more controlled patient-data capability—not a promise of clinical outcomes. Commercial scope is determined by the evidence, complexity, decisions and implementation support required.
Potential business and operating outcomes
- Clearer confidence in whether patient data is fit for a defined use
- Earlier detection of identity, mapping and clinical-data defects
- Stronger ownership across source, interface, data and clinical teams
- Better traceability from defect to root cause and remediation
- More consistent quality rules and exception handling
- Reduced ambiguity around interoperability transformations
- Stronger evidence for approved research, reporting and analytics use
- More controlled preparation of patient data for governed AI initiatives
- Repeatable release gates rather than one-time cleansing
- Operational monitoring that can detect recurrence and change
18A
Is Patient Data Quality the Right Starting Point?
Use this service when the immediate decision is about the fitness, reliability and control of patient or clinical data. Broader architecture or governance work can be added when the root causes extend beyond quality.
Good fit when…
- Patient records are duplicated, incomplete or inconsistent across systems.
- Clinical or operational teams do not trust a critical feed or data product.
- Data migration or interoperability releases need evidence-based acceptance.
- Research, registry or trial extracts require stronger traceability and quality controls.
- Analytics or AI teams need a governed patient-data readiness baseline.
- Recurring defects are being corrected downstream without addressing root cause.
Another service may be needed first when…
- The primary problem is enterprise strategy, platform selection or cloud architecture rather than patient-data fitness.
- The organisation needs legal interpretation, regulatory certification or clinical-safety sign-off as the main deliverable.
- No accountable sponsor can define the intended use or approve patient-data rules.
- Source-system access and evidence cannot be provided in a controlled manner.
- The request is limited to building a dashboard without resolving definitions, ownership or source defects.
- The need is only temporary staffing rather than a governed consulting or transformation outcome.
18C
What DataConsultant Needs From the Client
Missing evidence should be recorded as a limitation rather than guessed. A strong engagement combines controlled technical access with accountable clinical, business and data-owner participation.
Sponsors & domain owners
Executive sponsor, clinical or research SMEs, patient-data owners, stewards, privacy, security, architecture and technology owners.
System & interface inventory
Source categories, data flows, interface specifications, mappings, terminology, implementation guides and platform context.
Controlled data samples
Approved, minimised or masked samples, dictionaries, profiles, quality reports and exception records sufficient for the agreed tests.
Policies, rules & evidence
Existing quality rules, issue logs, ownership model, controls, lineage, validation evidence, privacy constraints and known regulatory context.
18D
Why DataConsultant for This Patient Data Quality Problem
The value is in connecting patient-data quality to the operating process, architecture, governance and remediation path—not treating defects as isolated technical anomalies.
Evidence before opinion
Profiling, reproducible rules, source traceability and explicit limitations create a stronger basis for quality decisions.
Patient-context aware
Identity, longitudinal relationships, care or research use, terminology and domain review shape what “good quality” means.
Architecture + governance together
Quality controls are placed where defects originate and paired with ownership, lineage, privacy and release decisions.
Continuity into implementation
Assessment findings can move into remediation, re-testing, monitoring, managed operations and knowledge transfer.
19
Frequently Asked Questions
Common questions about Patient Data Quality consulting for healthcare and life-sciences organisations.
What does Patient Data Quality consulting include?
Patient Data Quality consulting can include critical-data-element definition, source and interface profiling, patient identity and duplicate analysis, completeness and validity rules, terminology and format checks, timeliness and consistency controls, interoperability conformance checks, root-cause analysis, remediation prioritisation, ownership design, monitoring and release-readiness evidence. Final scope is agreed around the intended patient-data use and risk.
Which healthcare and life-sciences processes can be covered?
Relevant processes can include registration and patient matching, encounters and care transitions, laboratory and medication workflows, scheduling, referrals, clinical documentation, billing and claims interfaces, registry and outcomes reporting, research extraction, clinical-trial data flows, data migration, interoperability exchange and approved analytics or AI pipelines. Only processes relevant to the agreed scope are assessed.
Which patient and clinical data domains are typically assessed?
Common domains include patient identity and demographics, encounters, diagnoses, problems, allergies, medications, observations, laboratory results, procedures, orders, imaging metadata, provider and facility reference data, consent and privacy context, research or trial participant data, provenance, terminology and interface metadata. The exact domains depend on the organisation and use case.
Can you assess EHR, HL7 and FHIR data?
Yes. The engagement can assess data exported from EHR or clinical systems and data moving through HL7 or FHIR-based interfaces where those technologies are in scope. Checks may cover mapping, required fields, code systems, cardinality or profile expectations, provenance, patient linkage, transformation defects and downstream fitness. The applicable implementation guide and version must be confirmed rather than assumed.
How do you handle patient identity and duplicate records?
DataConsultant can analyse identifier completeness, duplicate patterns, conflicting demographic attributes, merge and unmerge indicators, source-system keys and matching logic. Remediation recommendations distinguish data correction from master-patient-index or identity-process changes. Clinical and operational owners remain responsible for approving patient-identity decisions.
How is data quality severity defined?
Severity is defined against the intended use, affected process, patient-safety or operational impact, downstream dependency, detectability, control coverage and regulatory or evidence needs. Example labels such as critical, high, medium and low are only a starting point; thresholds and release actions must be approved by accountable business, clinical, data, risk and technology owners.
How are privacy and security handled during the engagement?
The work should minimise patient-level data exposure, use controlled access and approved environments, apply masking or de-identification where appropriate, limit extracts to what is needed, preserve auditability and follow agreed retention and disposal rules. Applicable privacy and security obligations depend on jurisdiction, entity type, role and data use, so formal legal interpretation remains with qualified privacy or legal advisers.
Does the service certify HIPAA, DPDP, FDA or GCP compliance?
No. DataConsultant can help map data-quality, evidence, access, traceability and control requirements to the agreed operating context, but the service does not itself provide legal certification, regulatory approval, clinical-safety sign-off or statutory audit. Formal applicability and compliance conclusions should be confirmed with appropriately qualified legal, regulatory, quality and clinical specialists.
Can Patient Data Quality support clinical-trial or research data?
Yes, when research or trial data is in scope. The engagement can assess completeness, consistency, timeliness, traceability, source-to-target mapping, participant linkage, controlled terminology, exception handling and evidence needed for review. Trial-specific requirements, protocol context, GCP responsibilities and regulated-system controls must be confirmed with the sponsor and relevant quality or regulatory functions.
Can this service improve data used for analytics and AI?
Yes. The service can assess whether approved patient or clinical datasets are sufficiently documented and fit for a defined analytical, machine-learning or generative-AI use. This may include missingness, representativeness, provenance, label quality, leakage risk, training or grounding inputs, evaluation datasets and monitoring expectations. It does not guarantee model accuracy or clinical performance.
What deliverables will we receive?
Typical deliverables can include a critical-data inventory, source and interface map, profiling baseline, patient-identity findings, data-quality rule catalogue, severity matrix, failure taxonomy, root-cause findings, interoperability or mapping findings, remediation backlog, ownership and escalation model, re-test summary, release-readiness pack and monitoring framework. The final list is confirmed during scoping.
What information should we prepare before starting?
Useful inputs include the business or clinical use case, source-system and interface inventory, data dictionaries, sample or masked datasets, data-flow and mapping documentation, existing quality rules, terminology or implementation guides, issue logs, ownership information, relevant policies and controls, monitoring reports, known regulatory context and access to accountable domain, clinical, data, privacy, security and technology stakeholders.
Can DataConsultant implement the remediation recommendations?
Yes. Implementation support can be scoped for rule engineering, data-pipeline controls, mapping correction, quality dashboards, issue workflows, metadata and lineage, data standardisation, governance setup, testing, release support, knowledge transfer and coordination with internal teams or existing vendors. Source-system or clinical-workflow changes require the appropriate client owners and specialist teams.
Can DataConsultant provide ongoing patient-data quality monitoring?
Yes. Ongoing support can include scheduled profiling, rule monitoring, threshold review, exception triage, quality reporting, recurring root-cause analysis, rule change control, release validation, governance support and continuous improvement for an agreed dataset and control estate.
How are timeline and pricing determined?
DataConsultant does not publish a fixed fee or duration for this Patient Data Quality service. Scope depends on the number of sources and interfaces, data domains, patient-identity complexity, volume and sampling approach, number of critical elements and rules, interoperability and terminology scope, stakeholder and jurisdictional complexity, privacy controls, remediation depth, testing cycles, onsite needs and whether ongoing monitoring is included. A quote is confirmed after discovery.
Build a Patient Data Quality Process You Can Defend
Partner with DataConsultant to evaluate patient-data fitness, trace defects to root cause, establish accountable controls and create a repeatable release and monitoring process.
Patient Data Quality Enquiry
Request a Patient Data Quality Scope Review
Share your contact details and a non-sensitive description of the requirement. DataConsultant can review the likely evidence, stakeholders, scope factors and appropriate next step.